Article
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
The Journal of clinical endocrinology and metabolism - 1 Jan 2009
Joshua Anthony M, Ezzat Shereen, Asa Sylvia L, Evans Andrew, Broom Reuben, Freeman Marc, Knox Jennifer J
Abstract excerpt
CONTEXT: Paragangliomas are tumors that develop from extraadrenal chromaffin cells. Approximately 20% of paragangliomas are malignant, and surgical resection is considered the primary treatment when possible. The optimal systemic treatment for advanced disease is undefined, due in part to lack of effective agents. Here we report our experience suggesting that sunitinib is an effective agent in this malignancy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.